Skip to main content
KRRO
NASDAQ Life Sciences

Korro Bio 提名 KRRO-121 进入临床开发用于治疗高氨血症，更新产品管线

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$11.004
Mkt Cap
$108.299M
52W Low
$5.204
52W High
$55.89
Market data snapshot near publication time

summarizeSummary

Korro Bio 宣布提名 KRRO-121 进入临床开发，用于治疗尿素循环障碍（UCDs）和肝性脑病（HE）中的高氨血症，瞄准潜在的多亿美元市场机会。这一重要的产品管线进展是其2025年第四季度和全年公司更新的一部分，更新中还包括了新的α-1抗胰蛋白酶缺乏症（AATD）项目的进展，该项目在交付策略转变后重新启动。虽然报告提到了财务结果，但文章中没有提供具体的数字。该公司还重申了其8500万美元私募的完成，这之前曾在3月9日宣布。KRRO-121的提名是这家小型生物制药公司的一个关键里程碑，标志着该公司向人类试验和可能具有转化性的治疗方法迈进。投资者现在将关注即将到来的监管申报和KRRO-121的临床研究启动。

在该公告发布时，KRRO的交易价格为$11.00，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.1亿。 52周交易区间为$5.20至$55.89。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed KRRO - Latest Insights

KRRO
Apr 16, 2026, 7:00 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Korro Bio Discloses Highly Dilutive $85M PIPE Financing at Deep Discount, Executive Departures
Sentiment: Negative
View Wiseek Article
KRRO
Mar 20, 2026, 5:03 PM EDT
Filing Type: 424B5
Importance Score:
7
Prospectus filed for resale of 7.65M shares by private placement investors
Sentiment: Negative
View Wiseek Article
KRRO
Mar 13, 2026, 5:05 PM EDT
Filing Type: S-3
Importance Score:
8
Korro Bio Registers $88.7M in Shares for Resale by Private Placement Investors
Sentiment: Negative
View Wiseek Article
KRRO
Mar 12, 2026, 7:32 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Major Investor NEA 17 Increases Stake in Korro Bio with $5M Private Placement Purchase
Sentiment: Positive
View Wiseek Article
KRRO
Mar 12, 2026, 4:12 PM EDT
Filing Type: 10-K
Importance Score:
8
Korro Bio Details Clinical Program Termination, Workforce Reductions, and $90.1M Capital Raise in Annual Report
Sentiment: Neutral
View Wiseek Article
KRRO
Mar 12, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
9
Korro Bio Secures $85M Financing, Extends Runway to 2028, and Nominates New Clinical Candidate
Sentiment: Neutral
View Wiseek Article
KRRO
Mar 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Korro Bio Nominates KRRO-121 for Clinical Development in Hyperammonemia, Updates Pipeline
Sentiment: Positive
View Wiseek Article
KRRO
Mar 09, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Korro Bio Secures $85M in Oversubscribed Private Placement, Extending Cash Runway into H2 2028
Sentiment: Positive
View Wiseek Article
KRRO
Mar 09, 2026, 7:31 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Korro Bio Secures $85M in Oversubscribed Private Placement
Sentiment: Neutral
View Wiseek Article
KRRO
Jan 27, 2026, 9:15 AM EST
Filing Type: 8-K
Importance Score:
8
Korro Bio Highlights "Blockbuster Potential" of KRRO-121 for Ammonia Control at Analyst Day
Sentiment: Positive
View Wiseek Article